Skip to main content
OpenTrials
Completed

NCT Number: NCT02600221

A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China

To investigate the distributions of the patients with ACOS, asthma and COPD over age 40 with chronic airflow limitation in China.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Sites must be tier 3 hospitals in China. Investigators will mainly be determined according to the following criteria:

  • Respiratory physicians working in the respiratory department of tier 3 hospitals
  • To include the expected number of patients in a maximum of 12 months, physicians should manage a reasonable number of asthma, COPD or ACOS over age 40 with persistent airflow limitation (post-BD FEV1/FVC<0.7).
  • Physicians should have patients' spirometric data available in the patient's medical files (post-BD FEV1%pred and post-BD FEV1/FVC).

This NIS will collect the data (e.g. medical record, patient or physician-reported data) from about 2000 consecutive outpatients with persistent airflow limitation(post-BD FEV1/FVC<0.7) in about 20 sites in China for one year. Each site will recruit about 50-150 patients successively.

The data will be collected under routine clinical practice. The treatments or examinations will be determined by their treating physicians. The data are expected to reflect the actual situation about ACOS.

The study population will be about 2000 outpatients, men or women, over age 40, with a clinical diagnosis of asthma, COPD or ACOS with persistent airflow limitation(post-BD FEV1/FVC<0.7)in China from Q4,2015 to Q3,2016.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Outpatients, age ≥ 40 years Clinically diagnosed as asthma, COPD/chronic bronchitis/emphysema or ACOS at least 12 months With persistent airflow limitation (post-BD FEV1/FVC<0.7) Signed informed consent forms

Exclusion criteria

Have been involved in other clinical trial within 3 months Having other respiratory diseases which can influence airflow, such as lung cancer, tuberculosis, pneumonia, bronchiectasis, etc With acute exacerbation Inability to understand the study procedures or inability/reluctance to answer questionnaire judged by the investigator

Treatment and study plan

Primary outcomes

  1. The proportion of ACOS among the patients over age 40 with persistent airflow limitation (post-BD FEV1/FVC<0.7) based on GINA and GOLD 2015 definition

    Time frame: one day

Secondary outcomes

  1. - The proportions of COPD and asthma, respectively, among the patients over age 40 with persistent airflow limitation (post-BD FEV1/FVC<0.7) based on GINA and GOLD 2015 definition.

    Time frame: one day

  2. - The distributions of the severity of airflow limitation according to GOLD lung function grading based on post-BD FEV1 in patients with ACOS, COPD or asthma.

    Time frame: one day

  3. - The distribution of groups according to GOLD 2015 group definition (A,B,C,D) in patients with ACOS or COPD.

    Time frame: one day

  4. - The distribution of medication by drug class in patients with ACOS, Asthma and COPD.

    Time frame: one day

  5. - The proportions of previous diagnosis as asthma/COPD/chronic bronchitis/emphysema in the ACOS patients.

    Time frame: one day

  6. The number of Acute exacerbations history in 12 months before the visit

    Time frame: one day

  7. The severity of Acute exacerbations history in 12 months before the visit

    Time frame: one day

  8. The days of hospitalization or emergency room visit of Acute exacerbations history in 12 months before the visit

    Time frame: one day

  9. Severity of ACOS patients evaluated using CAT (mild, moderate, severe and very severe) in ACOS patients

    Time frame: one day

  10. Severity of ACOS patients evaluated using ACQ-5 (complete control, good control and uncontrolled) in ACOS patients

    Time frame: one day

  11. Severity of ACOS patients evaluated using mMRC (0, 1, 2, 3 and 4) in ACOS patients

    Time frame: one day

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Nov 9, 2015
Registry last updated
Oct 17, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.